LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Open

SectorGezondheidszorg

8.88 5.59

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.44

Max

8.99

Belangrijke statistieken
By Trading Economics
Inkomsten	7.7M -73M
Verkoop	929K 18M
EPS	-0.828
Winstmarge	-401.495
Werknemers	260
EBITDA	7.4M -78M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+228.39% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-42M 802M
Vorige openingsprijs	3.29
Vorige sluitingsprijs	8.88

Nieuwssentiment

By Acuity

100%

320 / 344 Rangschikking in Healthcare

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jun 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Belangrijke Marktbewegers

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Marktinformatie

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Marktinformatie

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Acquisities, Fusies, Overnames

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Acquisities, Fusies, Overnames

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Marktinformatie

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Marktinformatie

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Marktinformatie

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Marktinformatie

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Marktinformatie

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Marktinformatie

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Acquisities, Fusies, Overnames

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Marktinformatie

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Marktinformatie

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Marktinformatie

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

228.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.11 USD 228.39%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

320 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.